NCT Number: NCT00102713
A Study for Treatment of Partial Seizures in Children
The purpose of the study is to assess the safety profile of the investigational medication, Depakote Sprinkle Capsules, in the treatment of partial seizures in children ages 3-10.
Looking for future studies?
Notify MeKey information
Conditions
Age range
3 year–10 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Neurology Clinic, P.C., Northport, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subject has diagnosis of partial seizures with/without secondary generalization, supported by:
- Observed ictal events consistent with partial seizures with/without secondary generalization; Documented by reliable observers
- 1 of following 3:
- EEG at some time in past demonstrating focal abnormalities consistent with partial seizures
- If the EEG is inconclusive or does not support partial seizures, then an MRI/CT will be done
- If the MRI/CT fails to support a diagnosis of partial seizures, the subject may still qualify based on the principal Investigator's clinical diagnosis
- Subject weighs at least 15 kg (33 lbs).
- Parent/caregiver is able to keep an accurate seizure diary.
Exclusion criteria
- Has had status epilepticus in the past 3 months prior to Screening
- Has a history of any of: Cardiac (including clinically important abnormality on ECG); Renal; Psychiatric (including psychosurgery); Oncologic; Endocrine; Metabolic; Pancreatic; Hepatic disease (including clinical/serological history of hepatitis); Urea cycle disorder
- Has: Expanding CNS neoplasm; Active CNS infection; Demyelinating disease; Degenerative neurological disease; Progressive encephalopathy; or any Progressive CNS disease
- Has platelet count less than or equal to 100,000/mcL
- Has blood chemistry ALT/AST value(s) greater than or equal to 2 times upper limit of normal at screening
- Requires anticoagulant drug therapy
- Receiving systemic chemotherapy
- Requires treatment with aspirin
- Subject is pregnant
- Has been on ketogenic diet within 30 days prior to screening
- Considered by investigator to be non-responder to valproate for treatment of epilepsy (e.g., Despite adequate trial with serum concentrations of 60 mcg/mL or greater, subject continues to have inadequate seizure control)
Treatment and study plan
Primary outcomes
-
Partial Seizure Rate at Week 4
Secondary outcomes
-
Adverse Events
-
WASI
-
WPPSI-III
-
BASC
-
UKU-Neurologic Assessment
-
Vital Signs
-
Clinical Laboratory Assessments
-
ECG
-
PK analysis
Sponsors and collaborators
Lead sponsor
Abbott
Industry
Registry information
Official study title
An Open Label Study for Treatment of Partial Seizures in Children
Important dates
- Study start
- 2005
- First posted
- Feb 2, 2005
- Registry last updated
- May 21, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age
NCT03340064
Brain Diseases, Central Nervous System Diseases
Fukuoka, Japan
View Trial DetailsPregabalin Versus Levetiracetam In Partial Seizures
NCT00537238
Brain Diseases, Central Nervous System Diseases
Duffel, Belgium
View Trial DetailsOnce-A-Day Pregabalin For Partial Seizures
NCT01262677
Brain Diseases, Central Nervous System Diseases
Northport, Alabama, United States
View Trial DetailsPregabalin Epilepsy Add-On Trial
NCT00141258
Nervous System Diseases, Neurologic Manifestations
Daegu, South Korea
View Trial Details